Business
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled
About this update from Pulmatrix, Inc.
[{"type":"text","content":"LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it will host a key opinion leader (KOL) webinar on PUR3100, Pulmatrix's orally inhaled dihydroergotamine (DHE) therapy for the treatment of acute migraine, on Friday, April 23, 2021 at 10:00am Eastern Time.\n\n \n \n \n \n \n \n\n \nThe webinar will feature presentations by KOLs Stewart J. Tepper, M.D., F.A.H.S., Geisel School of Medicine at Dartmouth, and Stephen Silberstein, M.D., F.A.C.P., Thomas Jefferson University. Dr. Tepper will discuss the current treatment landscape and unmet medical need in treating patients with acute migraine. Dr. Silberstein will talk about DHE therapy and the potential advantages of new DHE therapies in development.\nDr. Russell Clayton, Pulmatrix's Strategic Advisor and Medical Director, will then discuss the PUR3100 development plan and pre-clinical data. Ted Raad, Pulmatrix's CEO, will also provide a brief corporate overview, including the business strategy behind PUR3100, a dry powder iSPERSE formulation of DHE for pulmonary delivery to treat acute migraine. PUR3100 is currently in pre-clinical investigation as an orally inhaled migraine therapy with Phase 1 and Phase 2 data anticipated in 2022.\nA live Q&A session will follow the formal presentations. To register for the webinar, please click here.\nStewart J. Tepper, M.D., F.A.H.S. is a Professor of Neurology at the Geisel School of Medicine at Dartmouth College in Hanover, New Hampshire. He is Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Dr. Tepper received his undergraduate degree cum laude in the study of the nervous system/psychobiology from Yale College, New Haven, Connecticut, and attended Cornell University Medical College in New York City. He completed his Neurology residency at the Longwood Area Harvard program, Boston, Massachusetts, and has been board certified in Headache Medicine since 2006.\nDr. Tepper has been Director of the Scottsdale Headache Symposium CME course of the American Headache Society from 2008 to 2020. He was Editor-in-Chief of the journal Headache...